The US FDA has granted accelerated approval of [C#198600617:CSL] Behring's clotting agent RiaSTAP (fibrinogen concentrate (human)) for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, an orphan indication that affects 150-300 people in the US.
The US FDA has granted accelerated approval of CSL Behring's clotting agent RiaSTAP (fibrinogen concentrate (human)) for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, an orphan indication that affects 150-300 people in the US.
The biological is indicated for patients with afibrogenaemia (absence or very low levels of plasma fibrinogen) and hypofibrinogaenemia (levels below...
Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.
The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.
A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
